Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Phosphagenics — Investor Presentation (August 2018)
25 slides from Avecho Biotechnology's investor presentation, August 2018
Slide 1: Phosphagenics: Non-confidential Presentation
August 2018 Phosphagenics: Non-confidential Presentation www.phosphagenics.com (ASX : POH)
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation, and any representations made before, during or after the presentation, may include forward-looking statements regarding Phosphagenics’ intent, belief or expectations that are inherently subject to risks and uncertainties. These statements may be indicated by
Slide 3: A snapshot of Phosphagenics
A snapshot of Phosphagenics Innovative biopharmaceutical company headquartered in Australia • TPM® is a proprietary solubilisation / drug delivery technology combining multiple forms of Vitamin E (protected by 13+ patent Families) • Result of 15+ years R&D and over $100M investment • Pipeline of TPM
Slide 4: Experienced Management & Board with strong track record of success
Experienced Management & Board with strong track record of success Anna Legg, CFO & Company Secretary • 20+ yrs financial experience; joined Phosphagenics in 2013 • Experience with establishment of international Greg Collier, Chairman & Independent Director entities, statutory reporting, system • 20
Slide 5: TPM is at the core of Phosphagenics
TPM® is at the core of Phosphagenics “…Phosphagenics invented, developed, patented and is the sole global manufacturer and supplier of TPM® …” TPM® : • proprietary combination of 2 forms of phosphorylated Vitamin E (in specific ratio) • highly flexible technology with excellent safety profile • impr
Slide 6: TPM is flexible and has broad applicability
TPM® is flexible and has broad applicability Phosphagenics leverages TPM®’s flexibility and unique properties, data and broad patent portfolio across multiple lucrative markets Highly versatile with an excellent stability Human Health and safety profile Enhances injectable drug solubility, stability
Slide 7: Phosphagenics TPM Portfolio is growing across 3 Businesses
Phosphagenics TPM® Portfolio is growing across 3 Businesses: Human Health Business Animal Health & Nutrition Business Product Partner Res’ Dev’ Market Product Partner Res’ Dev’ Market Injectable Portfolio Pig, Poultry, Feed efficiency Daptomycin Cattle mastitis & fertility Propofol Veterinary Aquacu
Slide 8: Injectable Portfolio
Injectable Portfolio Pain Portfolio Animal Health Personal Care
Slide 9: TPM can overcome key challenges for injectable drugs
TPM® can overcome key challenges for injectable drugs The global Injectable Injectables account for more than 80% TPM® market is an immense of the world’s drug shortages2 can overcome opportunity1 important Problems with product quality cause challenges for $330B $790B 77% of sterile injectable shor
Slide 10: Our Injectable portfolio is the product of over 14 years research
Our “Injectable” portfolio is the product of over 14 years research, $100M investment and multiple global partnerships 2004 2011 2016 TPM identified TPM TPM as solubilizer Daptomycin Propofol TPM improves: formulation safety, clarity, tolerability, stability, reconstitution. 2018 Product TPM Advanta
Slide 11: TPM is proven to enhance solubility and stability in lead injectable formulations
TPM® is proven to enhance the solubility and stability in lead injectable formulations Product Benefits Status • TPM® reduces reconstitution time by more than half • TPM® doubles the shelf life • Later Phase Dev. (TBC) TPM®/ at room temperature, • Arbitration Outcome Daptomycin pending • TPM® potent
Slide 12: Injectable assets are fast and profitable
“Injectable” assets are fast and profitable Review Formulation Stability Toxicology 505b2 POC Clinical Proof of Concept ~12 mths 3 mths ~12 mths 12+ mths 12+ mths Reduced risk / new work required for additional assets Estimated 2030 US Market for Current TPM/Injectable Pipeline 2,000 1,800 $1.6 Bill
Slide 13: Phosphagenics' arbitration with Mylan over TPM/Daptomycin
Phosphagenics’ arbitration with Mylan is over TPM®/Daptomycin Signed agreements with Agila Specialties Private Ltd to develop and market 2011/12: Phosphagenics’ TPM®/Daptomycin injectable 2013: Strides Shasun (STR:IN NATL INDIA) sold Agila to Mylan (MYL (NASDAQ, TASE)) for ~US$1.4B Phosphagenics fil
Slide 14: Board of Directors recommends shareholder return
Board of Directors recommends shareholder return* If Phosphagenics is successful and receives a material payment from Mylan, the Board intends to recommend a return of capital* (after costs): 30% of net cash 50% of net cash 70% of net cash Calculation: proceeds + proceeds + proceeds up to between gr
Slide 15: Pain Portfolio
Injectable Portfolio Pain Portfolio Animal Health Personal Care
Slide 16: Phosphagenics' Human Health Pain Product portfolio is strong
Phosphagenics’ Human Health “Pain Product” portfolio is strong and benefits from global partnerships The global Pain market Opioids and NSAIDs account for about TPM® is also a significant ½ of total market1 can allow opportunity1 delivery of pain therapy $62B $88B Side effects and abuse of oral pain
Slide 17: TPM/Oxycodone patch performance in Phase 2a PHN trial
TPM®/Oxycodone patch performance in Phase 2a PHN trial supports further development Overall efficacy did not reach significance in total population but strong trend in specific subgroup Conclusion: Patch Performed well but local oxycodone treatment is not ideal for PHN pain Efficacy Performance Sust
Slide 18: TPM/Oxymorphone patch performance supports further development
TPM®/Oxymorphone patch performance supports further development Multiple dose clinical trial (sequential x 72 hour applications) • World’s first patch to deliver therapeutic levels of oxymorphone transdermally • 2 sequential patch application (in n=12), mean CMAX increases, Consistent delivery profi
Slide 19: Animal Health and Personal Care
Injectable Portfolio Pain Portfolio Animal Health Personal Care
Slide 20: Phosphagenics has a strong Animal Health portfolio
Phosphagenics has a strong “Animal Health” portfolio driven by recent strong trial data The global Animal TPM® Over 250,000 tons/year of vitamins for Feed Additive market is livestock nutrition expected by 20242 significantly a 3rd major improve live opportunity1 weight gain/ feed $18B $28B Use of a
Slide 21: Phosphagenics' Personal Care portfolio has multiple partnerships
Phosphagenics’ “Personal Care” portfolio has multiple partnerships generating growing recurring revenues Vital ET® and TPM® are in more than 100 Existing Dataset TPM® cosmetics worldwide supports and Vital ET® in Vital ET® as Personal Care anti-irritant & Demand exceeds10 tonnes/yr and production pr
Slide 22: Phosphagenics is an exciting investment opportunity
Phosphagenics is a exciting investment opportunity ~12mth cash (A$3.3M at 30 June 18); No Debt; Tax losses >A$100M Experienced Management / Board with strong track record of success Validated TPM® Technology through all three businesses • Portfolio including “world first” transdermal opioid patches,
Slide 23: We have delivered consistent news flow and target valuable newsflow
We have delivered consistent substantial news flow and target valuable newsflow over the next 6 months Commercial reformulation of TPM®/Oxymorphone Patch Human Health Complete Successful Results for Swine Feed Efficiency Program Animal Health Complete Successful results for Poultry Feed Efficiency P
Slide 24: Phosphagenics key statistics
Phosphagenics Innovative Biopharmaceutical Company Headquartered in Australia Key Statistics: ASX/OTCQX Code POH/PPGNY (listed 2004) Headquarters Melbourne, Australia Employees 12 Shares ~1.5 billion Cash ~12mth Cash ($3.3M at 30 June 2018) Revenue ~$1.2M (2017) Market Cap ~$27M (at $.018/share) 3 B
Slide 25: Melbourne Office contact details
www.phosphagenics.com Melbourne Office Unit A8, 2A Westall Road Hallmarc Business Park Dr Ross Murdoch, CEO & Managing Director Clayton VIC 3168 rmurdoch@phosphagenics.com Australia Tel: +61 3 9002 5000 Email: info@phosphagenics.com www.phosphagenics.com